Wai Han Su, Pathomwichaiwat Thanika, Suansanae Thanarat, Nathisuwan Surakit, Rattanavipanon Wipharak
Clinical Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-ayutthaya Road, Ratchathewi, Bangkok, 10400, Thailand.
Center for Meta-Analysis and Evidence Synthesis of Traditional and Alternative Therapies (META), Bangkok, Thailand.
BMC Complement Med Ther. 2025 Jul 29;25(1):292. doi: 10.1186/s12906-025-05045-z.
Turmeric has traditionally been used to treat various inflammatory conditions, including knee osteoarthritis (OA). There are multiple turmeric preparations available. However, the comparative effectiveness of these products remains unknown. This study aimed to assess the comparative effectiveness of turmeric products for knee OA outcomes by conducting a systematic review and network meta-analysis of randomized, controlled trials (RCTs).
PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov databases were searched up to August 2024, identifying RCTs that compared turmeric preparations and/or active comparators versus placebo. The primary outcome measured pain reduction, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), while secondary outcomes evaluated pain using other tools. Mean differences (MDs) were pooled using a random-effects model, and the concept of minimum clinically important difference (MCID) was considered.
Seventeen studies were included. All turmeric preparations significantly reduced WOMAC pain. The mean differences (MD, 95% CI) for WOMAC pain reduction were as follows: - 4.01 (-6.22, - 1.80) for conventional curcuminoid preparations (CT) plus active drug comparators (AC, defined as NSAIDs and acetaminophen), - 3.33 (-5.26, - 1.39) for AC, - 3.17 (-5.50, - 0.83) for CT, and - 2.47 (-3.27, - 1.67) for bioavailability-enhanced curcuminoid preparations (BE). The BE preparation also demonstrated a 30% reduction in WOMAC pain compared to placebo, reaching the MCID threshold. The BE + AC combination led to a 70% reduction in VAS pain compared to AC alone.
All turmeric preparations appear to be effective in reducing knee OA pain when used as monotherapy compared to placebo. However, the certainty of evidence remains low, indicating a need for further research.
CRD42023464749.
not applicable.
姜黄传统上用于治疗各种炎症性疾病，包括膝关节骨关节炎（OA）。有多种姜黄制剂可供使用。然而，这些产品的相对疗效仍不清楚。本研究旨在通过对随机对照试验（RCT）进行系统评价和网状荟萃分析，评估姜黄产品对膝关节OA结局的相对疗效。
检索截至2024年8月的PubMed、EMBASE、SCOPUS和ClinicalTrials.gov数据库，确定比较姜黄制剂和/或活性对照与安慰剂的RCT。主要结局使用西安大略和麦克马斯特大学骨关节炎指数（WOMAC）测量疼痛减轻情况，次要结局使用其他工具评估疼痛。使用随机效应模型汇总平均差异（MD），并考虑最小临床重要差异（MCID）的概念。
纳入17项研究。所有姜黄制剂均显著减轻WOMAC疼痛。WOMAC疼痛减轻的平均差异（MD，95%CI）如下：传统姜黄素制剂（CT）加活性药物对照（AC，定义为非甾体抗炎药和对乙酰氨基酚）为-4.01（-6.22，-1.80），AC为-3.33（-5.26，-1.39），CT为-3.17（-5.50，-0.83），生物利用度增强的姜黄素制剂（BE）为-2.47（-3.27，-1.67）。与安慰剂相比，BE制剂还使WOMAC疼痛降低30%，达到MCID阈值。与单独使用AC相比，BE + AC组合使视觉模拟评分（VAS）疼痛降低70%。
与安慰剂相比，所有姜黄制剂作为单一疗法使用时似乎都能有效减轻膝关节OA疼痛。然而，证据的确定性仍然较低，表明需要进一步研究。
PROSPERO注册号：CRD42023464749。
不适用。
